Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule

被引：8
作者：
Di Paolo, Antonello [1 ]
Bracarda, Sergio [2 ]
Arrigoni, Elena [1 ]
Danesi, Romano [1 ]
机构：
[1] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy
[2] Osped San Donato USL8, Ist Toscano Tumori, Med Oncol, Arezzo, Italy
来源：
FRONTIERS IN PHARMACOLOGY | 2017年 / 8卷
关键词：
sunitinib; metastatic renal cell carcinoma; efficacy; tolerability; pharmacokinetics; pharmacodynamics; TYROSINE KINASE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; ANTITUMOR-ACTIVITY; SU11248; TOXICITY; CANCER; MALATE;
D O I：
10.3389/fphar.2017.00523
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：4
相关论文
共 17 条
[1]   Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis [J].
Bracarda, S. ;
Iacovelli, R. ;
Boni, L. ;
Rizzo, M. ;
Derosa, L. ;
Rossi, M. ;
Galli, L. ;
Procopio, G. ;
Sisani, M. ;
Longo, F. ;
Santoni, M. ;
Morelli, F. ;
Di Lorenzo, G. ;
Altavilla, A. ;
Porta, C. ;
Camerini, A. ;
Escudier, B. .
ANNALS OF ONCOLOGY, 2015, 26 (10) :2107-2113
[2]   A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period [J].
Britten, Carolyn D. ;
Kabbinavar, Fairooz ;
Hecht, J. Randolph ;
Bello, Carlo L. ;
Li, Jim ;
Baum, Charles ;
Slamon, Dennis .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) :515-524
[3]   Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [J].
DePrimo, Samuel E. ;
Bello, Carlo L. ;
Smeraglia, John ;
Baum, Charles M. ;
Spinella, Dominic ;
Rini, Brian I. ;
Michaelson, M. Dror ;
Motzer, Robert J. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5
[4]   Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer [J].
Faivre, S ;
Delbaldo, C ;
Vera, K ;
Robert, C ;
Lozahic, S ;
Lassau, N ;
Bello, C ;
Deprimo, S ;
Brega, A ;
Massimini, G ;
Armand, JP ;
Scigalla, P ;
Raymond, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :25-35
[5]   Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma [J].
Gore, M. E. ;
Szczylik, C. ;
Porta, C. ;
Bracarda, S. ;
Bjarnason, G. A. ;
Oudard, S. ;
Lee, S-H ;
Haanen, J. ;
Castellano, D. ;
Vrdoljak, E. ;
Schoeffski, P. ;
Mainwaring, P. ;
Hawkins, R. E. ;
Crino, L. ;
Kim, T. M. ;
Carteni, G. ;
Eberhardt, W. E. E. ;
Zhang, K. ;
Fly, K. ;
Matczak, E. ;
Lechuga, M. J. ;
Hariharan, S. ;
Bukowski, R. .
BRITISH JOURNAL OF CANCER, 2015, 113 (01) :12-19
[6]   Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients [J].
Griffioen, Arjan W. ;
Mans, Laurie A. ;
de Graaf, Annemarie M. A. ;
Nowak-Sliwinska, Patrycja ;
de Hoog, Celine L. M. M. ;
de Jong, Trees A. M. ;
Vyth-Dreese, Florry A. ;
van Beijnum, Judy R. ;
Bex, Axel ;
Jonasch, Eric .
CLINICAL CANCER RESEARCH, 2012, 18 (14) :3961-3971
[7]   Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis [J].
Houk, Brett E. ;
Bello, Carlo L. ;
Poland, Bill ;
Rosen, Lee S. ;
Demetri, George D. ;
Motzer, Robert J. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) :357-371
[8]   A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients [J].
Houk, Brett E. ;
Bello, Carlo L. ;
Kang, Dongwoo ;
Amantea, Michael .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2497-2506
[9]   Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate [J].
Liu, Glenn ;
Jeraj, Robert ;
Vanderhoek, Matt ;
Perlman, Scott ;
Kolesar, Jill ;
Harrison, Michael ;
Simoncic, Urban ;
Eickhoff, Jens ;
Carmichael, Lakeesha ;
Chao, Bo ;
Marnocha, Rebecca ;
Ivy, Percy ;
Wilding, George .
CLINICAL CANCER RESEARCH, 2011, 17 (24) :7634-7644
[10]  
Mendel DB, 2003, CLIN CANCER RES, V9, P327
12